Patents by Inventor Ingela VIKSTROM

Ingela VIKSTROM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING OR PREVENTING ISCHEMIA-REPERFUSION INJURY
    Publication number: 20230279129
    Abstract: The present disclosure relates to a method for preventing or treating ischemia-reperfusion injury in a subject the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation. In some examples, the compound is an antibody.
    Type: Application
    Filed: January 10, 2023
    Publication date: September 7, 2023
    Applicant: CSL Limited
    Inventors: Ingela VIKSTROM, Adriana BAZ MORELLI, Martin PEARSE
  • POLYPEPTIDES FOR INDUCING TOLERANCE TO FACTOR VIII
    Publication number: 20220348637
    Abstract: The present invention relates to polypeptides comprising (i) a VWF moiety and (ii) an erythrocyte-binding moiety, wherein the polypeptide is capable of binding to blood coagulation factor VIII (FVIII). The erythrocyte-binding moiety may be selected from the group consisting of a peptide ligand, an antibody, an antibody fragment, and a single chain antigen binding domain (scFv). The polypeptides may be provided as a heterodimer. The polypeptides are useful for inducing tolerance to FVIII.
    Type: Application
    Filed: November 11, 2020
    Publication date: November 3, 2022
    Inventors: Marco HOFMANN, Adriana BAZ MORELLI, Ingela VIKSTROM, Thomas WEIMER
  • METHOD OF TREATING OR PREVENTING ISCHEMIA-REPERFUSION INJURY
    Publication number: 20210179721
    Abstract: The present disclosure relates to a method for preventing or treating ischemia-reperfusion injury in a subject the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation. In some examples, the compound is an antibody.
    Type: Application
    Filed: November 29, 2018
    Publication date: June 17, 2021
    Applicant: CSL Limited
    Inventors: Ingela VIKSTROM, Adriana BAZ MORELLI, Martin PEARSE